Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khisimuzi Mdluli

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Opinion in Pharmacology|August 15, 2006
Novel targets for tuberculosis drug discoveryKhisimuzi Mdluli, Melvin Spigelman
Infectious Disorders Drug Targets|November 1, 2007
Mycobacterium tuberculosis DNA gyrase as a target for drug discoveryKhisimuzi Mdluli, Zhenkun Ma
Future Medicinal Chemistry|September 2, 2011
Challenges and opportunities in developing novel drugs for TBTakushi Kaneko, Christopher Cooper, Khisimuzi Mdluli
Annals of the New York Academy of Sciences|June 13, 2014
Tuberculosis drug discovery and emerging targetsKhisimuzi Mdluli, Takushi Kaneko, Anna Upton
Cold Spring Harbor Perspectives in Medicine|January 31, 2015
The tuberculosis drug discovery and development pipeline and emerging drug targetsKhisimuzi Mdluli, Takushi Kaneko, Anna Upton
Antimicrobial Agents and Chemotherapy|February 2, 2021
Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant <i>Rv0678</i> Mutant in a Mouse Model of TuberculosisJian Xu, Paul J Converse, Anna M Upton, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2023
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisDeepak Almeida, Si-Yang Li, Jin Lee, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisSi-Yang Li, Rokeya Tasneen, Sandeep Tyagi, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2016
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosisDeepak Almeida, Thomas Ioerger, Sandeep Tyagi, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2024
A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approachMaral Budak, Laura E Via, Danielle M Weiner, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Opinion in Pharmacology|August 15, 2006
Novel targets for tuberculosis drug discoveryKhisimuzi Mdluli, Melvin Spigelman
Infectious Disorders Drug Targets|November 1, 2007
Mycobacterium tuberculosis DNA gyrase as a target for drug discoveryKhisimuzi Mdluli, Zhenkun Ma
Future Medicinal Chemistry|September 2, 2011
Challenges and opportunities in developing novel drugs for TBTakushi Kaneko, Christopher Cooper, Khisimuzi Mdluli
Annals of the New York Academy of Sciences|June 13, 2014
Tuberculosis drug discovery and emerging targetsKhisimuzi Mdluli, Takushi Kaneko, Anna Upton
Cold Spring Harbor Perspectives in Medicine|January 31, 2015
The tuberculosis drug discovery and development pipeline and emerging drug targetsKhisimuzi Mdluli, Takushi Kaneko, Anna Upton
Antimicrobial Agents and Chemotherapy|February 2, 2021
Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant <i>Rv0678</i> Mutant in a Mouse Model of TuberculosisJian Xu, Paul J Converse, Anna M Upton, et al.
Antimicrobial Agents and Chemotherapy|November 15, 2023
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisDeepak Almeida, Si-Yang Li, Jin Lee, et al.
Antimicrobial Agents and Chemotherapy|June 21, 2017
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisSi-Yang Li, Rokeya Tasneen, Sandeep Tyagi, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2016
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosisDeepak Almeida, Thomas Ioerger, Sandeep Tyagi, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2024
A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approachMaral Budak, Laura E Via, Danielle M Weiner, et al.
Pageof 2